151 related articles for article (PubMed ID: 35678886)
1. Loss of H3K27me3 in WHO grade 3 meningioma.
Maier AD; Brøchner CB; Mirian C; Haslund-Vinding J; Bartek J; Ekström TJ; Poulsen FR; Scheie D; Mathiesen T
Brain Tumor Pathol; 2022 Oct; 39(4):200-209. PubMed ID: 35678886
[TBL] [Abstract][Full Text] [Related]
2. The substantial loss of H3K27me3 can stratify risk in grade 2, but not in grade 3 meningioma.
Jung M; Kim SI; Lim KY; Bae J; Park CK; Choi SH; Park SH; Won JK
Hum Pathol; 2021 Sep; 115():96-103. PubMed ID: 34186055
[TBL] [Abstract][Full Text] [Related]
3. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
4. Loss of H3K27me3 expression enriches in recurrent grade 1&2 meningiomas and maintains as a biomarker stratifying progression risk.
Hua L; Ren L; Wu Q; Deng J; Chen J; Cheng H; Wang D; Chen H; Xie Q; Wakimoto H; Gong Y
J Neurooncol; 2023 Jan; 161(2):267-275. PubMed ID: 36329368
[TBL] [Abstract][Full Text] [Related]
5. Loss of H3K27me3 in meningiomas.
Nassiri F; Wang JZ; Singh O; Karimi S; Dalcourt T; Ijad N; Pirouzmand N; Ng HK; Saladino A; Pollo B; Dimeco F; Yip S; Gao A; Aldape KD; Zadeh G;
Neuro Oncol; 2021 Aug; 23(8):1282-1291. PubMed ID: 33970242
[TBL] [Abstract][Full Text] [Related]
6. Impact of H3K27 trimethylation loss in meningiomas: a meta-analysis.
Cello G; Patel RV; McMahon JT; Santagata S; Bi WL
Acta Neuropathol Commun; 2023 Jul; 11(1):122. PubMed ID: 37491289
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Value of Histopathological Features and Loss of H3K27me3 Immunolabeling in Anaplastic Meningioma: A Multicenter Retrospective Study.
Gauchotte G; Peyre M; Pouget C; Cazals-Hatem D; Polivka M; Rech F; Varlet P; Loiseau H; Lacomme S; Mokhtari K; Kalamarides M; Bielle F
J Neuropathol Exp Neurol; 2020 Jul; 79(7):754-762. PubMed ID: 32447376
[TBL] [Abstract][Full Text] [Related]
8. H3K27me3 loss indicates an increased risk of recurrence in the Tübingen meningioma cohort.
Behling F; Fodi C; Gepfner-Tuma I; Kaltenbach K; Renovanz M; Paulsen F; Skardelly M; Honegger J; Tatagiba M; ; Schittenhelm J; Tabatabai G
Neuro Oncol; 2021 Aug; 23(8):1273-1281. PubMed ID: 33367841
[TBL] [Abstract][Full Text] [Related]
9. The Emerging Relevance of H3K27 Trimethylation Loss in Meningioma: A Systematic Review of Recurrence and Overall Survival with Meta-Analysis.
Lu VM; Luther EM; Eichberg DG; Morell AA; Shah AH; Komotar RJ; Ivan ME
World Neurosurg; 2022 Jul; 163():87-95.e1. PubMed ID: 35439620
[TBL] [Abstract][Full Text] [Related]
10. Long-term prognosis for atypical and malignant meningiomas: a study of 71 surgical cases.
Palma L; Celli P; Franco C; Cervoni L; Cantore G
J Neurosurg; 1997 May; 86(5):793-800. PubMed ID: 9126894
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and treatment of World Health Organization grade II and III meningiomas in childhood: report of 23 cases.
Wang XQ; Jiang CC; Zhao L; Gong Y; Hu J; Chen H
J Neurosurg Pediatr; 2012 Nov; 10(5):423-33. PubMed ID: 22938082
[TBL] [Abstract][Full Text] [Related]
12. TERT promoter mutations in primary and secondary WHO grade III meningioma.
Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
[TBL] [Abstract][Full Text] [Related]
13. Assessment of candidate immunohistochemical prognostic markers of meningioma recurrence.
Csonka T; Murnyák B; Szepesi R; Bencze J; Bognár L; Klekner A; Hortobágyi T
Folia Neuropathol; 2016; 54(2):114-26. PubMed ID: 27543769
[TBL] [Abstract][Full Text] [Related]
14. Altered expression of epigenetic modifiers EZH2, H3K27me3, and DNA methyltransferases in meningiomas - prognostic biomarkers for routine practice.
Samal S; Patnaik A; Sahu F; Purkait S
Folia Neuropathol; 2020; 58(2):133-142. PubMed ID: 32729292
[TBL] [Abstract][Full Text] [Related]
15. Clinical and histopathological predictors of outcome in malignant meningioma.
Maier AD; Bartek J; Eriksson F; Ugleholdt H; Juhler M; Broholm H; Mathiesen TI
Neurosurg Rev; 2020 Apr; 43(2):643-653. PubMed ID: 30868425
[TBL] [Abstract][Full Text] [Related]
16. [Meningiomas: new prognostic factors].
Sanz Esponera J
An R Acad Nac Med (Madr); 2007; 124(2):319-32; discussion 330-2. PubMed ID: 18069599
[TBL] [Abstract][Full Text] [Related]
17. Distinguishing chordoid meningiomas from their histologic mimics: an immunohistochemical evaluation.
Sangoi AR; Dulai MS; Beck AH; Brat DJ; Vogel H
Am J Surg Pathol; 2009 May; 33(5):669-81. PubMed ID: 19194275
[TBL] [Abstract][Full Text] [Related]
18. Expression of the stem cell marker CD133 in malignant meningioma.
Maier AD; Mirian C; Bartek J; Juhler M; Bartkova J; Broholm H; Mathiesen TI
Clin Neuropathol; 2021; 40(3):151-159. PubMed ID: 33250074
[TBL] [Abstract][Full Text] [Related]
19. WHO grade II and III meningiomas: a study of prognostic factors.
Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
[TBL] [Abstract][Full Text] [Related]
20. WHO grade of intracranial meningiomas differs with respect to patient's age, location, tumor size and peritumoral edema.
Ressel A; Fichte S; Brodhun M; Rosahl SK; Gerlach R
J Neurooncol; 2019 Nov; 145(2):277-286. PubMed ID: 31578671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
